SLXN today
$2.66-$0.57 (-17.65%)close Nov 12, 2026Trend
DailyUptrend (starting)
4 hourExpanding
1 hourExpanding
15 minSymmetric Triangle
5 minStrong Bearish
Daily trend turns down below $12973.50
Key levels
Resistance$13041.00
Resistance$12973.50
Latest news & SEC filings
NewsSilexion Therapeutics to consolidate shares 24-to-1, adjusted trading begins November 11
All SLXN news →About Silexion Therapeutics
Silexion Therapeutics is a clinical-stage oncology biotechnology firm working on therapies for tumors linked to KRAS gene mutations. Its main product, SIL204, uses small interfering RNA to shut down the mutated KRAS gene, given both into the tumor and by injection under the skin together with standard chemotherapy. The company first targets locally advanced pancreatic cancer and also studies colorectal and lung cancers. It runs its operations through an Israeli subsidiary and intends to hold trials in Israel, Germany, other parts of Europe, and the United States.
Based on the company's 10-K filed Mar 17, 2026.
Nasdaq · Healthcare
Silexion Therapeutics Corp (SLXN)
What Is the Price Target for SLXN?
SEPT Low Target
$0.00
SEPT Mid Target
$0.00
SEPT High Target
$0.00
Analyst Consensus
$0.00
Is SLXN a Buy or Sell Right Now?
AI-Powered Trading Signals
Trained on trillions of real market data to read price action and give you a simple, emotionless trading strategy for SLXN.
Start Free Trial →Is SLXN Overvalued or Undervalued?
Valuation Verdict
N/A
Methods Used
N/A
Fair Value
$N/A
7
Moat Score
NONE
4/9
Piotroski Score
-15.3
Altman Z-Score
What Is Smart Money Doing with SLXN?
Insider Signal
NEUTRAL
0 buys / 0 sells (90d)
Congress Signal
NEUTRAL
0 buys / 0 sells (90d)
Institutional
ACCUMULATING
Short Squeeze Risk
LOW
Signal: NEUTRAL
Recent Insider Activity
| Name | Title | Type | Shares | Value | Date |
|---|---|---|---|---|---|
| Shirvan Mitchell | officer | Buy | 6,000 | - | Jun 4, 2026 |
| Horenshtein Hadar Mirit | officer | Buy | 7,500 | - | Jun 4, 2026 |
| Hadar Ilan | director officer | Buy | 10,000 | - | Jun 4, 2026 |
Track Smart Money Across 4,000+ Stocks
Insider trades, congress trades, institutional flows, and short interest — updated daily with real-time alerts.
See All Smart Money Signals →SLXN Growth Story
Revenue YoY
N/A%
3yr Revenue CAGR
N/A%
EPS Growth YoY
-97.73%
FCF Growth YoY
-28.6%
Revenue Trend
UNKNOWN
Dark Pool Trades for SLXN
PREVIEWSEPT Investing tracks real-time dark pool institutional trades for SLXN, including block trade sizes, dollar values, and buy/sell side classification. Dark pool trades reveal where institutional investors are positioning before moves become visible on public exchanges.
| Time | Price | Size | Value | Side |
|---|---|---|---|---|
| 18:58:43 | $2.75 | 2,000 | $$6K | BUY |
| 18:52:11 | $2.72 | 3,000 | $$8K | BUY |
| 16:58:05 | $3.00 | 1,000 | $$3K | BUY |
| 16:58:03 | $3.00 | 1,000 | $$3K | MIDPOINT |
| 16:58:01 | $3.00 | 1,000 | $$3K | BUY |
5 dark pool trades shown · $$23K preview volume
Real-time institutional flow, block trades, and net positioning
Full AI Research Report
SEPT's Trading AI has generated a free, downloadable PDF research report for Silexion Therapeutics Corp (SLXN) covering valuation analysis, financial health assessment, growth projections, smart money tracking, earnings and key price levels. For research only, not investment advice.
Report includes: PDF download, detailed valuation models (DCF, P/E, EV/EBITDA), institutional flow analysis, congress and insider trade tracking, FinBERT news sentiment (1 articles analyzed), and SEC filing intelligence...
AI-Powered Trading Signals.
Trained on trillions of real market data to read price action and give you a simple, emotionless trading strategy. SEPT tells you when to buy, when to sell, and grades every stock so you never trade blind.
Try SEPT Free for 7 Days →SLXN — frequently asked questions
What is SLXN stock price today?
Silexion Therapeutics Corp (SLXN) is at $2.66, down 17.65% (-$0.57) at the Nov 12, 2026 close.
Why is SLXN stock moving today?
Latest SLXN news — Nov 9, 2026: Silexion Therapeutics to consolidate shares 24-to-1, adjusted trading begins November 11
What do analysts rate SLXN?
Analyst ratings for SLXN: 1 Buy, 1 Hold, 0 Sell — consensus Buy.
Did SLXN beat earnings?
SLXN last reported on Aug 14, 2026: EPS -$5.17 vs -$21.20 expected — a beat of 75.6%.
Does SLXN pay a dividend?
SLXN does not currently pay a dividend.
What are SLXN support and resistance levels?
Resistance: $12973.50, $13041.00, $13081.50.
What are insiders doing with SLXN?
Insider activity: NEUTRAL, 0 buys and 0 sells in the last 90 days.
What is the latest news on SLXN?
Nov 9, 2026: Silexion Therapeutics to consolidate shares 24-to-1, adjusted trading begins November 11